Acylated nonadepsipeptides

Details Acylated nonadepsipeptides Acylated nonadepsipeptides

2008-05-06

2008-05-06

Tsang, Cecilia J. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S317000

Reexamination Certificate

active

07368424

ABSTRACT:
The invention relates to nonadepsipeptides and process for their preparation, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.

REFERENCES:
patent: 4754018 (1988-06-01), Tymiak et al.
patent: 2005/0075281 (2005-04-01), Von Nussbaum et al.
patent: 0196042 (1986-01-01), None
patent: 01132600 (1989-05-01), None
patent: WO2004099239 (2004-11-01), None
Tenover. Mechanisms of antimicrobial resistance in bacteria. Am Infect Control 2006. vol. 34, pp. S3-S10.
Maki et al. Katanosin B and Plusbacin A3 , Inhibitors of Peptidoglycan Synthesis in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, Jun. 2001, pp. 1823-1827.
Palomo, C., Oiarbide, M., Ganboa, I., Miranda, J., “A concise synthesis of α-amino acid N-carboxy anhydrides of (2S, 3S)-β-substituted serines”, Tetrahedron Letts., 42: 8955-8957 (2001).
Harada, K., Suzuki, M., Kato, A., Fujii, K., Oka, H., Ito, Y., “Separation of WAP-8294A components, a novel anti-methicillin-resistantStaphylococcus aureusantibiotic, using high-speed counter-current chromatography”, J. of Chrom. A., 932 75-81 (200l).
Egner, B., Bradley, M., “Monitoring the solid phase synthesis of analogues of lysobactin and the katanosins usingin situMALDI-TOF MS”, Tetrahedron, 53(41): 14021-14030 (1997).
Tymiak, A., McCormick, T., Unger, S., “Structure determination of lysobactin, a macrocyclic peptide lactone antibiotic”, J. Org. Chem., 54: 1149-1157 (1989).
Green, D., “The bacterial cell wall as a source of antibacterial targets”, Expert Opin. Ther. Targets, 6:1-19 (2002).
Baquero, F., “Gram-positive resistance: challenge for the development of new antibiotics”, J. Antimicrob. Chemo., 39(Supp. A): 1-6 (1997).
Johnson, A., Livemore, D., Tillotson, G., “Antimicrobial susceptibility of Gram-posititve bacteria: what's current, what's anticipated?”, J. Hosp. Infect., 49(Supp. A): S3-S11 (2001).
Goldrick, B., “First reported care of VRSA in the United States”, Am. J. Nurs., 102:17 (2002).
O'Sullivan, J., McCullough J., Tymiak, A., Kirsch, D., Trejo, W., Principe, P., “Lysobactin, a novel antibacterial agent produced bylysobacter sp.”, J. Antibiot., 41: 1740-1744 (1988).
Bonner, D., O'Sullivan, J., Tanaka, S.K., Clark, J., Whitney, R., “Lysobactin, a novel antibacterial agent produced bylysobacter sp.”, J. Antibiot., 41: 1745-1751 (1988).
Shoji, J., Hinoo, H., Matsumoto, K., Hattori T., Yoshida, T., Matsurra, S., Kondo, E., “Isolaton and characterization of Katanosins A and B”, J.. Antibiot, 41(6): 713-718 (1988).

Affiliated with

Also associated with

Rating

Acylated nonadepsipeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Acylated nonadepsipeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylated nonadepsipeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2784402